Advanced search
Publication Cover
Current Medical Research and Opinion Volume 26, 2010 - Issue 8
Submit an article Journal homepage
286
Views
38
CrossRef citations to date
0
Altmetric
Commentary

Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative (R3i)

J.C. Fruchart Ri Foundation, Paris, FranceCorrespondence[email protected]
,
F.M. Sacks Harvard School of Public Health, Harvard Medical School; Brigham and Women’s Hospital, Boston, MA, USA
,
M.P. Hermans Cliniques Universitaires St-Luc, Service d’Endocrinologie et Nutrition, Brussels, Belgium
& on behalf of the International Steering Committee of R3i
Pages 1793-1797 | Accepted 26 Apr 2010, Published online: 19 May 2010

Citations (38)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Kamini Trivedi, Viet Le & John R. Nelson. (2021) The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. Postgraduate Medicine 133:1, pages 28-41.
Read now
Shitalkumar P Zambad, Davinder Tuli, Anoop Mathur, Sameer A Ghalsasi, Anita R Chaudhary, Shailesh Deshpande, Ramesh C Gupta, Vijay Chauthaiwale & Chaitanya Dutt. (2014) TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity. Diabetes, Metabolic Syndrome and Obesity 7, pages 1-14.
Read now
Julian P Halcox. (2013) Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega–3 polyunsaturated fatty acid ethyl esters. Clinical Lipidology 8:3, pages 329-344.
Read now
DJ Blom. (2011) Secondary dyslipidaemia. South African Family Practice 53:4, pages 317-323.
Read now
Michel P Hermans & Jean-Charles Fruchart. (2010) Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?. Clinical Lipidology 5:6, pages 811-826.
Read now

Articles from other publishers (33)

Donna Vine, Ethan Proctor, Olivia Weaver, Mahua Ghosh, Katerina Maximova & Spencer Proctor. (2021) A Pilot Trial: Fish Oil and Metformin Effects on ApoB-Remnants and Triglycerides in Women With Polycystic Ovary Syndrome. Journal of the Endocrine Society 5:9.
Crossref
Donna F Vine, Lawrence J Beilin, Sally Burrows, Rae-Chi Huang, Martha Hickey, Roger Hart, Spencer D Proctor & Trevor A Mori. (2020) ApoB48-Lipoproteins Are Associated with Cardiometabolic Risk in Adolescents with and without Polycystic Ovary Syndrome. Journal of the Endocrine Society 4:8.
Crossref
Juan F. Ascaso, Jesús Millán, Antonio Hernández-Mijares, Mariano Blasco, Ángel Brea, Ángel Díaz, Juan Pedro-Botet & Xavier Pintó. (2020) Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society. Clínica e Investigación en Arteriosclerosis (English Edition) 32:3, pages 120-125.
Crossref
Juan F. Ascaso, Jesús Millán, Antonio Hernández-Mijares, Mariano Blasco, Ángel Brea, Ángel Díaz, Juan Pedro-Botet & Xavier Pintó. (2020) Dislipidemia aterogénica 2019. Documento de consenso del Grupo de Dislipidemia Aterogénica de la Sociedad Española de Arteriosclerosis. Clínica e Investigación en Arteriosclerosis.
Crossref
Mariano Blasco & Juan F. Ascaso. (2019) Control del perfil lipídico global. Clínica e Investigación en Arteriosclerosis 31, pages 34-41.
Crossref
M. Kupreeva, A. Diane, R. Lehner, R. Watts, M. Ghosh, S. Proctor & D. Vine. (2019) Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. American Journal of Physiology-Endocrinology and Metabolism 316:1, pages E16-E33.
Crossref
Michel P. Hermans & Paul Valensi. (2018) Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes. Current Opinion in Endocrinology & Diabetes and Obesity 25:2, pages 118-129.
Crossref
Winfried März, Marcus E. Kleber, Hubert Scharnagl, Timotheus Speer, Stephen Zewinger, Andreas Ritsch, Klaus G. Parhofer, Arnold von Eckardstein, Ulf Landmesser & Ulrich Laufs. (2017) HDL cholesterol: reappraisal of its clinical relevance. Clinical Research in Cardiology 106:9, pages 663-675.
Crossref
Juan F. Ascaso, Jesús Millán, Antonio Hernández-Mijares, Mariano Blasco, Ángel Brea, Ángel Díaz, Teresa Mantilla, Juan Pedro-Botet & Xavier Pintó. (2017) Documento de consenso sobre el manejo de la dislipemia aterogénica de la Sociedad Española de Arteriosclerosis. Clínica e Investigación en Arteriosclerosis 29:2, pages 86-91.
Crossref
Juan F. Ascaso, Jesús Millán, Antonio Hernández-Mijares, Mariano Blasco, Ángel Brea, Ángel Díaz, Teresa Mantilla, Juan Pedro-Botet & Xavier Pintó. (2017) Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis. Clínica e Investigación en Arteriosclerosis (English Edition) 29:2, pages 86-91.
Crossref
W. März, M. E. Kleber, H. Scharnagl, T. Speer, S. Zewinger, A. Ritsch, K. G. Parhofer, A. von Eckardstein, U. Landmesser & U. Laufs. (2016) Klinische Bedeutung des HDL-CholesterinsClinical importance of HDL cholesterol. Herz 42:1, pages 58-66.
Crossref
Patricia Freitas Corradi, Nidhi Agrawal, Namrata Gumaste & Ira J. Goldberg. 2017. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus 533 550 .
Paul Valensi, Antoine Avignon, Ariane Sultan, Bernard Chanu, Minh Tuan Nguyen & Emmanuel Cosson. (2016) Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study. Cardiovascular Diabetology 15:1.
Crossref
Jes?s Mill?n, Antonio Hern?ndez-Mijares, Juan F. Ascaso, Mariano Blasco, Angel Brea, ?ngel D?az, Pedro Gonz?lez-Santos, Teresa Mantilla, Juan Pedro-Botet & Xavier Pint?. (2016) La aut?ntica dimensi?n del colesterol-no-HDL: colesterol aterog?nico. Cl?nica e Investigaci?n en Arteriosclerosis 28:6, pages 265-270.
Crossref
Juan F. Ascaso & Rafael Carmena. (2015) Importancia de la dislipidemia en la enfermedad cardiovascular: un punto de vista. Cl?nica e Investigaci?n en Arteriosclerosis 27:6, pages 301-308.
Crossref
Patricia Freitas Corradi, Nidhi Agrawal, Namrata Gumaste & Ira J. Goldberg. 2016. Principles of Diabetes Mellitus. Principles of Diabetes Mellitus 1 19 .
Michel P. Hermans, Sylvie A. Ahn & Michel F. Rousseau. (2014) Parental brevity linked to cardiometabolic risk in diabetic descendants. Journal of Diabetes and its Complications 28:2, pages 141-146.
Crossref
Michel P Hermans, Sylvie A Ahn & Michel F Rousseau. (2014) Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipids. Cardiovascular Diabetology 13:1, pages 56.
Crossref
Behzad Salari, Shabnam Samankan & Jahan Porhomayon. 2014. Glucose Intake and Utilization in Pre-Diabetes and Diabetes. Glucose Intake and Utilization in Pre-Diabetes and Diabetes 21 28 .
Michel P Hermans, Sylvie A Ahn & Michel F Rousseau. (2012) The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. Lipids in Health and Disease 11:1.
Crossref
Laurent Querton, Martin Buysschaert & Michel P. Hermans. (2012) Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. Journal of Clinical Lipidology 6:5, pages 434-442.
Crossref
Gillian M. Keating & Kate McKeage. (2012) Fenofibrate: a guide to its use in dyslipidaemia. Drugs & Therapy Perspectives 28:4, pages 5-10.
Crossref
Susan R. Kirsh & David C. Aron. (2011) Choosing Targets for Glycaemia, Blood Pressure and Low-Density Lipoprotein Cholesterol in Elderly Individuals with Diabetes Mellitus. Drugs & Aging 28:12, pages 945-960.
Crossref
Kate McKeage & Gillian M. Keating. (2011) Fenofibrate. Drugs 71:14, pages 1917-1946.
Crossref
Michel P. Hermans & Jean-Charles Fruchart. (2011) Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians. Therapeutic Advances in Chronic Disease 2:5, pages 307-323.
Crossref
Gillian M. Keating. (2011) Fenofibrate. American Journal Cardiovascular Drugs 11:4, pages 227-247.
Crossref
Alexander K. Tsai, Brian T. Steffen, Jose M. Ordovas, Robert Straka, Xia Zhou, Naomi Q. Hanson, Donna Arnett & Michael Y. Tsai. (2011) Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants. Translational Research 158:2, pages 99-105.
Crossref
Arnold von Eckardstein & Rahel A Sibler. (2011) Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Current Opinion in Lipidology 22:1, pages 26-32.
Crossref
Yan Dong, Brian T. Steffen, Jing Cao, Alexander K. Tsai, Jose Ordovas, Robert Straka, Xia Zhou, Edmond Kabagambe, Naomi Q. Hanson, Donna Arnett & Michael Y. Tsai. (2011) Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants. Atherosclerosis 214:2, pages 422-425.
Crossref
Yasushi WakidaSatoshi SuzukiHirohiko Nomura, on behalf of APPROACH-J InvestigatorsTatsuya Isomura. (2011) Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study). Japanese Clinical Medicine 2, pages JCM.S7863.
Crossref
Kuo-Liong Chien, Hung-Ju Lin, Hsiu-Ching Hsu & Ming-Fong Chen. (2011) Lipid-related residual risk and renal function for occurrence and prognosis among patients with first-event acute coronary syndrome and normal LDL cholesterol. Lipids in Health and Disease 10:1, pages 215.
Crossref
Jesús Millán Núñez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Salas, Antonio Hernández Mijares, Vincent J. Carey, Michel P. Hermans, Frank M. Sacks & Jean-Charles Fruchart. (2011) Estudio REALIST (REsiduAl risk, LIpids and Standard Therapies): Un análisis del Riesgo Residual dependiente del perfil lipídico en el síndrome coronario agudo. Endocrinología y Nutrición 58:1, pages 38-47.
Crossref
Jesús Millán Núñez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Salas, Antonio Hernández Mijares, Vincent J. Carey, Michel P. Hermans, Frank M. Sacks & Jean-Charles Fruchart. (2011) The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome. Endocrinología y Nutrición (English Edition) 58:1, pages 38-47.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.